The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Track record suggest that any surprises , wont be good ones.
PL , add to that, why is pay/benefits not linked to SP performance
If you listen to early interviews with Smith he was talking about major inflection points and multiple tests and the revenue opportunity.
So far it's all been the emperors new clothes. If the words and the reality continue to be misaligned, he must step aside
It's a waste of people's time taking the SP down, AS an
d the board are proficient at that.
If it fails tomorrow would the other options be likely to work? I thought this would prove the platform or otherwise
They clearly haven't heard that we are at the start of a value curve.
Don't understand why AS is never held to account for the constantly changing strategy. Fine to adapt if there is a good reason but he never gives an explanation therefore it's understandable that it appears that the can is just been booted down the road. It's back to the old issue of poor communication
Question were selected so its impossible to say that nothing was off the table, without seeing the full list of questions
"Yeah pretty much, ok let’s park this then and see if he gets voted out at the AGM"
What happens at the AGM wont determine who was right or wrong. If he gets voted out you could still be right and visa versa.
Good to be able to discuss without it getting heated and personal so thank you.
I don't feel that AS has returned any value for LTHs , I haven't seen any near term inflection points or starts of value curves. The SP was a 39.99 on 9th April 2020.
We have a CEO that repeatedly writes cheques that he cannot cash.
My issue is with the man at the top not the science or the operation.
You are happy with AS behind the steering wheel and I'm not. Nothing either of us say will change the others view .
Time will tell which one of us was right.
I cannot knock your positivity but its impossible for me to ignore what has happened.
AS clattered every hurdle with LFT and we are seeing more of the same.
I'm sure he has good people working for him but the buck stops with him, he is the CEO not Simon.
I personally believe it needs change, if not we have years more of the same - shambolic commercial decisions, armature comms. If you are happy with everything as it is , fine but I personally would like a safer pair of hands.
Ice.
And yet here we are.
It doesn't matter what either of us think or hope this might be worth, the market doesn't see it the same way.
Until there is a clear explanation as to why the £26m plus and a 50p SP was a better than "optionality, no dilutive funding, spin DX, don't worry, nudge and wink" it's understandable why Simon's CV alone isn't enough to move things in the right direction.
The science “working” is only half the battle, you need the structure and commercial know how to bring it to fruition.
AS is seen as AVACTA, his reputation is tarnished, he is commercially incompetent and therefore the brand and trust is damaged.
As Myles said, management and board have managed to mess things up over the last 4 years. Alastair has very little credit in the bank. His track record is of promising much and delivering little.
It feels like blind faith to believe that, this time he has something up his sleeve and can be trusted as a pair of safe hands to effectively and efficiently navigate the business to success.
Other than those looking for a quick profit, who is going to invest long term when the CEO’s word cannot be believed .
It needs a change at the top, a rebrand.
IMO part of the issue is the CEO’s ego. “The next roche”.
Avacta are trying spinning too many plates. It’s too big for him to manage. Its like an 6 year old being given Lego Creator Expert Taj Mahal,
The approach to comms isn’t a mistake it’s a choice . Its often ambiguous and inconsistent,. I think that is a symptom of what is happening in the business.
AS occasionally popping his head out from behind the curtain and muttering , don’t worry, just getting on with it, value curve, holy grail etc has stopped convincing many.
Hi Ice.
Avactas approach to comms isn't winning any friends or building trust.
Big pharma don't need to create trust because they have already earned it.
That's the worry. Working as designed, sounds encouraging but what if the design isn't right. Once again its down to interpretation of the words. AS is the master of ambiguity. Avacta's approach isn't due to a lack of understanding of the benefits of clear and concise communication, its an active choice. You have to ask why. To rebuild trust it has to change.
Step aside Elizabeth Holmes
Thanks.
Maybe being picky but I think its another example of poor comms. The rns gave no indication as to when the valuation would happen and we still don't know.
Its good news it should be capitalised on
We are in March and we still don't know what the benefit of hitting the milestone is or have any indication when we will know.
It would be interesting to know what hitting the second milestone means in terms of our shareholding